Recursion Pharmaceuticals, a biotech company leveraging AI and automation, faces financial struggles and uncertain future despite its innovative approach to drug discovery.

Recursion Pharmaceuticals Inc. reported Q1 2025 earnings, beating estimates, but faced increased losses amid restructuring efforts, while advancing its strategic focus on oncology and rare diseases.

Recursion Pharmaceuticals reports promising results from its clinical trial of REC-4881, a potential treatment for Familial Adenomatous Polyposis (FAP), showing a 43% median reduction in polyp burden at Week 13.